Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Semin Immunol. 2015 Nov 30;28(1):22–27. doi: 10.1016/j.smim.2015.11.002

Table 2.

Outstanding questions for cancer immunotherapy targeting neoantigens.

1. How does this approach overcome the heterogeneity of tumor?
2. Does the number of neoantigens correlate with the mutation rate in each tumor
specimen?
3. Can this approach apply to a variety types of cancers, especially cancers with low
mutation rate?
4. Can neoantigens induce tolerance? Can Treg specifically recognize neoantigens and
induce tolerance?
5. Are the number and fitness of neoantigen-specific T cells important for the efficacy of
cancer immunotherapy?